Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for its Category 1 chemical drug HP537, targeting hematologic malignancies. This development marks a significant step for Hinova Pharmaceuticals as it advances its pipeline in oncology.
HP537 is an in-house developed small molecule anti-tumor drug that functions by binding to the p300/CBP bromine domain (BRD), thereby inhibiting the p300/CBP signaling pathway. This mechanism of action blocks the progression, growth, and differentiation of tumor cells. The drug is currently in development for the treatment of multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), among other hematologic malignancies. Notably, there is no similar product commercially available globally at this time, highlighting the potential innovation and impact of HP537 in the treatment landscape for these diseases.
The green light from the CDE to proceed with clinical studies for HP537 underscores the potential of Hinova Pharmaceuticals to contribute to the global oncology space with a novel therapeutic option for patients suffering from hematologic malignancies.- Flcube.com
